Search Results for: 06939926
DMD: encouraging results for the PF-06939926 gene therapy product
A phase Ib trial of PF-06939926 in Duchenne muscular dystrophy among 9 patients shows that this gene therapy product allows dystrophin to be produced in the muscle and improves motor function, 12 months after the treatment has been injected. PF-06939926, developed by Pfizer, is a gene therapy drug candidate being evaluated for Duchenne muscular dystrophy … [Read more]
